Diagnostic and Prognostic Role of Serum Omentin and NGAL Levels in Egyptian Breast Cancer Patients.

IF 1.6 Q4 ONCOLOGY

International Journal of Breast Cancer Pub Date : 2022-09-14 eCollection Date: 2022-01-01 DOI:10.1155/2022/5971981

Al-Shimaa Mahmoud Abas, Mohamed H Sherif, Sara A Elmoneam Farag

{"title":"Diagnostic and Prognostic Role of Serum Omentin and NGAL Levels in Egyptian Breast Cancer Patients.","authors":"Al-Shimaa Mahmoud Abas, Mohamed H Sherif, Sara A Elmoneam Farag","doi":"10.1155/2022/5971981","DOIUrl":null,"url":null,"abstract":"Background: Breast cancer (BC) is globally the main cause of cancer-related deaths in women. Tumor biomarkers have significant role in diagnosis and predicting the prognosis and decide the specific therapy to each patient.Aim: In this study, we investigated whether omentin and NGAL levels were altered in patients with breast cancer and the relationship between these markers and their clinicopathological parameters. Subjects and Methods. This study included 120 patients with breast cancer and 30 healthy individuals served as controls. We measured the serum level of omentin and NGAL by ELISA technique.Results: Our results showed that there were statistically significant differences in serum omentin and NGAL levels between two groups. Also, in breast cancer patients, there was significant difference between omentin level, the same results with NGAL level and patient's age, tumor size, lymph node, and metastasis. No significant relationship was found between omentin level and tumor grade, ER, PR, and HER2. The cutoff value for the prediction of breast cancer was determined at >113.2 ng/ml for omentin and >145.3 ng/ml for NGAL with a sensitivity of 91.7% and 100%, specificity of 100% and 80%, positive predictive value of 100% and 90.9%, negative predictive value of 85.7% and 100%, and accuracy of 94.4% and 93.3%, respectively. In conclusion, serum omentin and NGAL can be used as strong diagnostic markers for breast cancer.","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2022 ","pages":"5971981"},"PeriodicalIF":1.6000,"publicationDate":"2022-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492437/pdf/","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Breast Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2022/5971981","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 3

Abstract

Background: Breast cancer (BC) is globally the main cause of cancer-related deaths in women. Tumor biomarkers have significant role in diagnosis and predicting the prognosis and decide the specific therapy to each patient.

Aim: In this study, we investigated whether omentin and NGAL levels were altered in patients with breast cancer and the relationship between these markers and their clinicopathological parameters. Subjects and Methods. This study included 120 patients with breast cancer and 30 healthy individuals served as controls. We measured the serum level of omentin and NGAL by ELISA technique.

Results: Our results showed that there were statistically significant differences in serum omentin and NGAL levels between two groups. Also, in breast cancer patients, there was significant difference between omentin level, the same results with NGAL level and patient's age, tumor size, lymph node, and metastasis. No significant relationship was found between omentin level and tumor grade, ER, PR, and HER2. The cutoff value for the prediction of breast cancer was determined at >113.2 ng/ml for omentin and >145.3 ng/ml for NGAL with a sensitivity of 91.7% and 100%, specificity of 100% and 80%, positive predictive value of 100% and 90.9%, negative predictive value of 85.7% and 100%, and accuracy of 94.4% and 93.3%, respectively. In conclusion, serum omentin and NGAL can be used as strong diagnostic markers for breast cancer.

Abstract Image

查看原文本刊更多论文

血清网膜蛋白和NGAL水平在埃及乳腺癌患者中的诊断和预后作用。

背景:乳腺癌(BC)是全球女性癌症相关死亡的主要原因。肿瘤生物标志物在诊断和预测预后以及决定每位患者的特异性治疗方面具有重要作用。目的:在本研究中，我们探讨乳腺癌患者网膜蛋白和NGAL水平是否发生改变，以及这些标志物与其临床病理参数的关系。研究对象和方法。这项研究包括120名乳腺癌患者和30名健康个体作为对照。采用ELISA法测定血清大网膜蛋白和NGAL水平。结果:我们的结果显示，两组患者血清网膜蛋白和NGAL水平差异有统计学意义。在乳腺癌患者中，网膜水平、NGAL水平与患者年龄、肿瘤大小、淋巴结、转移情况有显著性差异。网膜水平与肿瘤分级、ER、PR、HER2无显著相关性。预测乳腺癌的临界值，网膜entin >113.2 ng/ml, NGAL >145.3 ng/ml，敏感性分别为91.7%和100%，特异性分别为100%和80%，阳性预测值分别为100%和90.9%，阴性预测值分别为85.7%和100%，准确率分别为94.4%和93.3%。综上所述，血清大网膜蛋白和NGAL可作为乳腺癌的有力诊断指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Breast Cancer ONCOLOGY-

CiteScore

3.40

自引率

0.00%

发文量

审稿时长

19 weeks

期刊介绍： International Journal of Breast Cancer is a peer-reviewed, Open Access journal that provides a forum for scientists, clinicians, and health care professionals working in breast cancer research and management. The journal publishes original research articles, review articles, and clinical studies related to molecular pathology, genomics, genetic predisposition, screening and diagnosis, disease markers, drug sensitivity and resistance, as well as novel therapies, with a specific focus on molecular targeted agents and immune therapies.